161 related articles for article (PubMed ID: 16413429)
1. Antipsychotic drug use among nursing home residents taking rivastigmine.
Narayanan S; Beusterien KM; Thomas SK; Musher J; Strunk B
J Am Med Dir Assoc; 2006 Jan; 7(1):12-6. PubMed ID: 16413429
[TBL] [Abstract][Full Text] [Related]
2. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic drug use among nursing home residents taking rivastigmine.
Iraqi A; Hughes TL
J Am Med Dir Assoc; 2006 Jun; 7(5):337-8. PubMed ID: 16765876
[No Abstract] [Full Text] [Related]
4. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
[TBL] [Abstract][Full Text] [Related]
5. Impact of rivastigmine use on the risk of nursing home placement in a US sample.
Beusterien KM; Thomas SK; Gause D; Kimel M; Arcona S; Mirski D
CNS Drugs; 2004; 18(15):1143-8. PubMed ID: 15581384
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
[TBL] [Abstract][Full Text] [Related]
7. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Cummings JL; Koumaras B; Chen M; Mirski D;
Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
[TBL] [Abstract][Full Text] [Related]
8. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
9. The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivastigmine on the disruptive behavior of nursing home residents with Alzheimer's disease.
Hatoum HT; Lin SJ; Arcona S; Thomas SK; Koumaras B; Mirski D
J Am Med Dir Assoc; 2005; 6(4):238-45. PubMed ID: 16005409
[TBL] [Abstract][Full Text] [Related]
10. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
[TBL] [Abstract][Full Text] [Related]
11. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study.
Rege S; Carnahan RM; Johnson ML; Chen H; Holmes HM; Aparasu RR
Drugs Aging; 2021 Jun; 38(6):493-502. PubMed ID: 33763822
[TBL] [Abstract][Full Text] [Related]
13. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
Suh DC; Thomas SK; Valiyeva E; Arcona S; Vo L
Drugs Aging; 2005; 22(8):695-707. PubMed ID: 16060719
[TBL] [Abstract][Full Text] [Related]
14. Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings.
Grossberg GT
Drugs Aging; 2008; 25(7):573-84. PubMed ID: 18582146
[TBL] [Abstract][Full Text] [Related]
15. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
Hatoum HT; Thomas SK; Lin SJ; Lane R; Bullock R
J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974
[TBL] [Abstract][Full Text] [Related]
16. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
[TBL] [Abstract][Full Text] [Related]
17. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
20. Sex Differences in Antipsychotic and Benzodiazepine Prescribing Patterns: A Cohort Study of Newly Admitted Nursing Home Residents with Dementia in Ontario, Canada.
Maclagan LC; Maxwell CJ; Harris DA; Campitelli MA; Diong C; Lapane KL; Hogan DB; Rochon P; Herrmann N; Bronskill SE
Drugs Aging; 2020 Nov; 37(11):817-827. PubMed ID: 32978758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
